Evidence map›Paper›PMID 40230486›Full record

ArticleMatrix biology plus2025

Small Integrin binding Ligand N-linked Glycoproteins, prostate-specific antigen and time to prostate cancer diagnosis.

Alka Jain, Ying Ni, Daisy Zhang, Eleanor M Simonsick, E Jeffrey Metter, Kalu U Ogbureke, Larry W Fisher, Neal S Fedarko

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Matrix biology plus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Alka JainDepartment of Medicine, Johns Hopkins University, Baltimore, MD 21224, USA.
Ying NiResearch Laboratory Core, Institute for Clinical and Translational Research, Johns Hopkins University, Baltimore, MD 21224, USA.
Daisy ZhangResearch Laboratory Core, Institute for Clinical and Translational Research, Johns Hopkins University, Baltimore, MD 21224, USA.
Eleanor M SimonsickIntramural Research Program, National Institute on Aging, National Institutes of Health, Baltimore, MD 21225, USA.
E Jeffrey MetterIntramural Research Program, National Institute on Aging, National Institutes of Health, Baltimore, MD 21225, USA.
Kalu U OgburekeDepartment of Diagnostic & Biomedical Sciences, School of Dentistry, University of Texas Health Science Center at Houston, Houston, TX 77054, USA.
Larry W FisherMatrix Biochemistry Section, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD 20892, USA.
Neal S FedarkoDepartment of Medicine, Johns Hopkins University, Baltimore, MD 21224, USA.

Funding

Small Integrin-binding Glycophosphoproteins as Biomarkers for Prostate CancerR01CA149273 · NCI · JOHNS HOPKINS UNIVERSITY · PI FEDARKO, NEAL S · 2011 to 2013
$896k
NCI NIH HHS R01 CA149273
6 · The paper itself

Abstract

backgroundSmall Integrin Binding Ligand N-linked Glycoproteins (SIBLINGs

methodsA retrospective longitudinal case control study was performed to determine the association of SIBLINGs and prostate-specific antigen (PSA) with preclinical disease. Paired serum samples from 109 cancer-free Baltimore Longitudinal Study on Aging participants were divided into those that were either most distal or proximal to diagnosis (cases) or censored (controls). Dentin sialophosphoprotein (DSPP), bone sialoprotein (BSP), osteopontin (OPN), and PSA were measured by immunoassay and dichotomized into low or high based on their respective cut-off values. Associations of time to diagnosis or death, modeled as disease-free survival (DFS) or overall survival (OS), were assessed using Kaplan Meier and Cox proportional hazard survival estimates on individual and aggregated biomarkers in distal or proximal sets separately. Models were adjusted for relevant covariates. A false discovery rate analysis assessed significance of hazard ratios (HRs) in sets.

resultsBiomarkers/aggregates identified as true discoveries for DFS included DSPP + PSA, OPN + PSA, DSPP + BSP + PSA, DSPP + OPN + PSA, where unadjusted distal HRs ranged between 11 and 27 and after adjusting for age from 7 to 15, while proximal HRs ranged between 6 and 10 unadjusted and 5 to 12 after adjusting for age. For proximal OS, true discoveries included DSPP + BSP, DSPP + OPN, DSPP + BSP + OPN, and DSPP + OPN + PSA where unadjusted HRs ranged between 6 and 20 while age-adjusted HRs ranged between 5 and 12.

conclusionsThese observations support SIBLINGs as biomarkers that associate with DFS and OS in prediagnosis samples.

Indexed as

Bone sialoproteinDentin sialophosphoproteinOsteopontinPreclinicalProstate cancerProstate-specific antigen

Identifiers

PMID40230486
PMCPMC11995099

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.